Trastuzumab-based combination therapy for breast cancer

Bibliography

• AKIYAMA T, SUDO C, OGAWARA H et al.: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 232: 1644-1646.
   Google Scholar
• COUSSENS L, YANG-FENG TL, LIAO YC et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 230:1132–1139.
   PubMed Web of Science ®Google Scholar
• DOWNWARD J, YARDEN Y, MAYES E et al.: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 307:521–527.
   PubMed Web of Science ®Google Scholar
• SHIH C, PADHY LC, MURRAY M et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 290:261–264.
   PubMed Web of Science ®Google Scholar
• SEMBA K, KAMATA N, TOYOSHIMA K et al.: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA (1985) 82:6497–6501.
   PubMed Web of Science ®Google Scholar
• KING CR, KRAUS MH, AARONSON SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 229:974–976.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev Ma Cell. Biol. (2001) 2:127–137.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• ••The first paper addressing the adverseeffects of HER-2-overexpression on the outcome of breast cancer in humans.
   Google Scholar
• ROSS JS, FLETCHER JA: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. Clin. Pathol. (1999) 112:S53–S67.
   Google Scholar
• GUSTERSON BA, GELBER RD, GOLDHIRSCH A et al.: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Clin. Oncol (1992) 10:1049–1056.
   Google Scholar
• PRESS MF, BERNSTEIN L, THOMAS PA et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Clin. Oncol (1997) 15:2894–2904.
   Google Scholar
• HAMILTON A, PICCART M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann. Oncol (2000) 11:647–663.
   PubMed Web of Science ®Google Scholar
• ••A review describing the current status ofnewer prognostic and predictive factors in breast cancer.
   Google Scholar
• ELLIS MJ, COOP A, SINGH B et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. Clin. Oncol (2001) 19:3808–3816.
   Google Scholar
• TAGLIABUE E, AGRESTI R, CARCANGIU ML et al.: Role of HERZ in wound-induced breast carcinoma proliferation. Lancet (2003) 362:527–533.
   PubMed Web of Science ®Google Scholar
• ••The findings reported in this paper provideinsights into the possible mechanisms of post-surgical tumour progression in patients with operable HER-2-overexpressing breast cancer.
   Google Scholar
• KIM YS, KONOPLEV SN, MONTEMURRO F et al.: HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin. Cancer Res. (2001) 7:4008–4012.
   PubMed Web of Science ®Google Scholar
• HUDZIAK RIVI, LEWIS GD, WINGET M et al: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Ma Cell Biol. (1989) 9:1165–1172.
   Google Scholar
• FENDLY BM, WINGET M, HUDZIAK RIVI et al: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. (1990) 50:1550–1558.
   PubMed Web of Science ®Google Scholar
• PIETRAS RJ, FENDLY BM, CHAZIN VR et al.: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 9: 1829-1838.
   Google Scholar
• BASELGA J, MENDELSOHN J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol The]: (1994) 64:127–154.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, ALBANELL Jet al.: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. (1998) 58:2825–2831.
   Google Scholar
• PEGRAM M, HSU S, LEWIS G et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene (1999) 18:2241–2251.
   PubMed Web of Science ®Google Scholar
• ••The predinical observations described inthis paper provide the rationale for clinical trials combining trastuzurnab with chemotherapy.
   Google Scholar
• PEGRAM MD, LOPEZ A, KONECNY G et al.: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol (2000) 27:21–25.
   PubMed Web of Science ®Google Scholar
• SLIWKOWSKI MX, LOFGREN JA, LEWIS GD et al.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol (1999) 26:60–70.
   PubMed Web of Science ®Google Scholar
• •A description of mechanisms possibly involved in trastuzurnab anti-tumour activity.
   Google Scholar
• PETIT AM, RAK J, HUNG MC et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. Pathol. (1997) 151:1523–1530.
   PubMed Web of Science ®Google Scholar
• Roche Herceptin Product Monograph (2001). Gardiner-Kaldwell Ltd. Communications. Macclesfield, Cheshire, UK.
   Google Scholar
• BASELGA J, TRIPATHY D, MENDELSOHN J et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Clin. Oncol. (1996) 14:737–744.
   Web of Science ®Google Scholar
• PEGRAM MD, LIPTON A, HAYES DF et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. j Clin. Oncol (1998) 16:2659–2671.
   PubMed Web of Science ®Google Scholar
• TUBBS RR, PETTAY JD, ROCHE PC et al.: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent Immunohistochemical false-positives do not get the message. Clin. Oncol (2001) 19:2714–2721.
   Google Scholar
• ••The concordance of various techniquesto assess HER-2 status is addressed in this paper.
   Google Scholar
• MASS RD, PRESS M, ANDERSON S et al.: Improved survival benefit from Herceptin (Trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc. Am. Soc. Old Oncol (2001) 20:22a (Abstract 85).
   Google Scholar
• •Patients selected on the basis of FISH positivity achieved the maximum benefit of trastuzumab in this retrospective analysis of patients who participated in the pivotal trial.
   Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al: Multinational study of the efficacy and safety of humanized anti-HERZ monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol (1999) 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• ••A large Phase II trial studying the activityof single-agent trastuzumab in patients with prior exposure to chemotherapy for metastatic breast cancer.
   Google Scholar
• VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. I. Clin. Oncol (2002) 20:719–726.
   PubMed Web of Science ®Google Scholar
• ••A large Phase II trial studying the activityof single-agent trastuzumab in patients without prior exposure to chemotherapy for metastatic breast cancer.
   Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HERZ for metastatic breast cancer that overexpresses HERZ. N Engl. J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• •A Phase III trial of chemotherapy with or without trastuzumab, demonstrating a prolongation of survival in patients receiving trastuzumab.
   Google Scholar
• FORNIER M, RISIO M, VAN POZNAK C et al.: HERZ testing and correlation with efficacy of trastuzumab therapy. Oncology (Hunting) (2002) 16:1340–1342.
   Google Scholar
• •An algoritm for HER-2 testing in the evaluation of candidates to therapy with trastuzumab.
   Google Scholar
• LEYLAND-JONES B: Dose scheduling-Herceptin. Oncology (Huntingt) (2001) 61\(Suppl. 2):31–36.
   Google Scholar
• CARBONEL CASTELLON X, CASTANETA-SOTO NJ, CLEMENS M et al.: Efficacy and safety of 3-weekly herceptin (H) monochemotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a Phase II trial. Proc. Am. Soc. Clin. Oncol (2002) 21:19a (Abstract 73).
   Google Scholar
• •The first study showing that the 3-weekly schedule of trastuzumab is feasible and clinically active.
   Google Scholar
• FUCHS C, LANDT S, BUETHLER H et al.: Analysis of HER1 and HERZ in the Heart to Clarify the Cardiotoxicity of Herceptin. Proc. Am. Soc. Clin. Oncol (2001) 20:45a (Abstract 176).
   Google Scholar
• BEHR TM, BEHE M, WORMANN B: Trastuzumab and breast cancer. N Engl. J. Med. (2001) 345:995–996.
   PubMed Web of Science ®Google Scholar
• CRONE SA, ZHAO YY, LIAN F et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. (2002) 8:459–465.
   PubMed Web of Science ®Google Scholar
• KEEFE DL: Trastuzumab-associated cardiotoxicity. Cancer (2002) 95:1592–166.
   PubMed Web of Science ®Google Scholar
• ••A clinically useful definition of risk factorsfor trastuzumab-related cardiotoxicity.
   Google Scholar
• SPARANO JA: Taxanes for breast cancer: an evidence-based review of randomized Phase II and Phase III trials. Clin. Breast Cancer (2000) 1:32–40.
   PubMedGoogle Scholar
• ROBERT N, LEYLAND-JONES B, ASMAR L et al: Phase III comparative study of trastuzumab and paclitaxel with and without caboplatin in patients with HER-2/neupositive advanced breast cancer. Breast Cancer Res. Treat. (2002) 76:S37. (Abstract 35).
   Google Scholar
• •The preliminary results of this trial show a potential advantage from the addition of carboplatin to paclitaxel and trastuzumab.
   Google Scholar
• SEIDMAN AD, FORNIER MN, ESTEVA FJ et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HERZ immunophenotype and gene amplification. Clin. Oncol (2001) 19:2587–2595.
   Web of Science ®Google Scholar
• •This paper addresses the response rate to weekly paclitaxel and trastuzumab according to a panel of different methods for assessing the HER-2 status af the tumour.
   Google Scholar
• FOUNTZILAS G, TSAVDARIDIS D, KALOGERA-FOUNTZILA A et al.: Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group Phase II study. Ann. Oncol (2001) 12:1545–1551.
   Google Scholar
• YEUNG KY, GUPTA R, HAIDAK D et al.: Weekly (W) herceptin® (H, traztwdmab) and one hour taxol (T, paclitaxel) infusion (WHT) regimen for human epidermal growth factor receptor-2 (HER2) overexpressed (+) metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol (2000) 19:142a (Abstract 559).
   Google Scholar
• JOHN M, KRIEBELL-SCHMITT R, STAUCH M et al: Trastuzumab combined with weekly paclitaxel treatment in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:54 (Abstract 217).
   Google Scholar
• GASPARINI G, GION M, CRIVELLARI D et al.: Interim analysis of a randomized Phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC): clinical and biological results. Proc. Am. Soc. Clin. aryl (2003) 22:35 (Abstract 138).
   Google Scholar
• LEYLAND-JONES B, GELMON K, AYOUB JP et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. j Chit. Oncol (2003) 21:3965–3971.
   PubMed Web of Science ®Google Scholar
• ••The first fully-published paper using a 3-weekly schedule of trastuzumab in combination with chemotherapy.
   Google Scholar
• LUCK HJ, ROCHE H: Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit. Rev Oncol Hematol (2002) 44:S15–S30.
   Google Scholar
• KRASNA L, JANKU F, PETRUZELKA L et al.: Herceptin (H) and taxol (T) in the treatment of women with HER-2/Neu overexpressing metastatic breast cancer (MBC): prospective study. Proc. Am. Soc. Clin. Oncol (2001) 20:606 (Abstract 2006).
   Google Scholar
• CHOLLET 0, MOREAU L, MOURET-REYNER MA et al.: Addition of herceptin to taxol for HER-2 over-expressing advanced breast cancer (ABC). Best results in skin metastasis. Proc. Am. Soc. Clin. Oncol (2001) 20:6813 (Abstract 2020).
   Google Scholar
• SCHOLZ U, LUCK HJ, SCHIPPERT C Trastuzumab (Herceptin) combined with weekly paclitaxel in the treatment of metastatic breast cancer, a Phase II study. Breast Cancer Res. Treat. (2000) 64:S122 (Abstract 527).
   Google Scholar
• MRSIC M, BOGDANIC V, LABAR B et al.: Trastuzumab plus pacfitaxel in the treatment of advanced breast cancer: single-centre experience. Ann. Oncol. (2000) 11:32 (Abstract 132P).
   Google Scholar
• ESTEVA FJ, VALERO V, BOOSER D et al.: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Clin. Oncol. (2002) 20:1800–1808.
   Web of Science ®Google Scholar
• UBER KA, NICHOLSON BP, THOR AD et al.: A Phase II trial of weekly docetaxel (D) and herceptin (H) as first or second-fine treatment in HERZ over-expressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:506 (Abstract 1949).
   Google Scholar
• MEDEN H, BENEKE A, HESSE T et al:Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anti-Cancer Res. (2001) 21:1301–1305.
   PubMedGoogle Scholar
• MALIK U, SPARANO JA, MANALO J et al.: Phase II trial of weekly docetaxel (taxotere) alone or in combination with trastuzumab (herceptin) in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:148a (Abstract 586).
   Google Scholar
• MONTEMURRO F, CHOA G, FAGGIUOLO R et al.: A Phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:48 (Abstract 191).
   Google Scholar
• BURRIS HA, III: Docetaxel (Taxotere) plustrastuzumab (Herceptin) in breast cancer. Semin. Oncol. (2001) 28:38–44.
   PubMedGoogle Scholar
• RAAB G, BRUGGER W, HARBECK N et al.: Multicenter randomized Phase II study of docetaxel (Doc) given q3w versus q lw plus trastuzumab (Tra) as first line therapy for HERZ overexpressing adjuvant anthracycfine pretreated metastatic breast cancer. Breast Cancer Res. Treat. (2002) 76:S114 (Abstract 443).
   Google Scholar
• EXTRA JM, COGNETTI F, CHAN S et al.: Randomised Phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eui: J. Cancer (2003) 1:S202 (Abstract 672).
   Google Scholar
• •In this randomised Phase II trial, the addition of trastuzumab to docetaxel resulted in increased response rate and survival parameters compared to docetaxel alone.
   Google Scholar
• MONTEMURRO F, CHOA G, FAGGIUOLO R et al: Safety and activity of docetaxel and trastuzumab in HERZ overexpressing metastatic breast cancer. A pilot Phase II study. Am. J. Clin. Oncol (2003) 26:95–97.
   PubMed Web of Science ®Google Scholar
• DOMENECH GH, VOGEL CL: A reviewof vinorelbine in the treatment of breast cancer. Clin. Breast Cancer (2001) 2:113–128.
   PubMedGoogle Scholar
• BURSTEIN HJ, KUTER I, CAMP OS SM et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Clin. Oncol. (2001) 19:2722–2730.
   Google Scholar
• JAHANZEB M, MORTIMER JE, YUNUS F et al.: Phase II trial of weekly vinorelbine and trastuzumab as first-fine therapy in patients with HERZ+ metastatic breast cancer. Oncologist (2002) 7:410–417.
   PubMed Web of Science ®Google Scholar
• BERNARDO G, PALUMBO R, BERNARDO A et al.: Weekly trastuzumab (Herceptin) and vinorelbine (Navelbine) in chemonaive patients with HERZ overexpressing metastatic breast cancer: a Phase II trial. Ann. Oncol. (2002) 13:51 (Abstract 181P).
   Google Scholar
• CHAN A, UNTCH M, PETRUZELKA L et al.: Multinational Phase II trial of Navelbine (N) and Herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HERZ+ MBC). Breast Cancer Res. Treat. (2002) 76:S112 (Abstract 434).
   Google Scholar
• FILIPOVICH E, MAJORDOMO JI, ISLA D et al.: Chemotherapy with trastuzumab plus vinorelbine in patients with erb-B2 overexpressed tumor is active in metastatic breast cancer. Breast Cancer Res. Treat. (2002) 76:S112 (Abstract 436).
   Google Scholar
• PAPALDO P, FABI A, SINO MS et al: Comparison between vinorelbine (V) in HER2-negative and vinorelbine plus trastuzumab (T) in HER2-positive pretreated metastatic breast cancer (MBC) cancer patients (pts). Proc. Am. Soc. Clin. Oncol. (2003) 22:74 (Abstract 296).
   Google Scholar
• BURSTEIN HJ, HARRIS LN, MARCOM PK et al.: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumour markers as predictive factors and cardiac surveillance algorithm. J. Clin. Oncol. (2003) 21:2889–2895.
   PubMed Web of Science ®Google Scholar
• ••The authors studied an algorithm for theearly identification of patients at risk for trastuzumab-related cardiotoxicity.
   Google Scholar
• NABHOLTZ JM, PIENOWSKI T, NOTHFELT D et al: Results of two open label multicentre Phase II pilot studies with herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene. Eur: J. Cancer (2001) 37:S190 (Abstract 695).
   Google Scholar
• ••This abstract reports the results of twopilot studies conducted to establish a non-anthracydine containing association of trastuzumab and polichemotherapy to be used in a Phase III trial in the adjuvant setting.
   Google Scholar
• BRUFSKY AM, CLEARY D, FUCHS C et al.: First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): a Phase II trial. Proc. Am. Soc. Clin. Omni (2003) 22:18 (Abstract 71).
   Google Scholar
• YARDLEY DA, GRECO FA, HAINSWORTH JD et al.: Final results of the Minnie Pearl Cancer Research Network first-fine trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res. Treat. (2002) 79:S113 (Abstract 439).
   Google Scholar
• ROWLAND KM, SUMAN VJ, INGLE JN et al: NCCTG 98-32-52: randomized Phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HERZ positive metastatic breast cancer. Proc. Am. Soc. Clin. Omni (2003) 22:8 (Abstract 31).
   Google Scholar
• GIANNI L, ALBANELL J, EIERMANN W et al.: Feasibility, pharmacology, and antitumor activity of herceptin® (H) with doxorubicin and taxol followed by weekly taxol (AT&T) in women with HERZ-positive advanced breast cancer (ABC). Proc. Am. Soc. Clin. Oncol. (2001) 20:44a (Abstract 174).
   Google Scholar
• LUNARDI G, VANNOZZI MO, BIGHIN C et al.: Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann. Omni (2003) 14:1222–1226.
   Google Scholar
• THOMSSEN CH, EIDTMANN H, UNTCH M et al.: Cardiac safety of epepirubicin/cyclophosphamide alone and in combination with Herceptin in women with metastatic breast cancer. Breast Cancer Res. Treat. (2002) 76:S111 (Abstract 430).
   Google Scholar
• VENTURINI M, NICOLETTO 0, BIGHIN C et al.: A multicenter Phase II study of trastuzumab with epirubicin and docetaxel as first line treatment in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:34 (Abstract 134).
   Google Scholar
• THE ODOULOU M, CAMPOS SM, BATIST G et al: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final results cardiac safety and efficacy analysis. Proc. Am. Soc. Clin. Oncol (2002) 21:55a (Abstract 216).
   Google Scholar
• WOLFF AC, BONETTI M, SPARANO JA et al.: Cardiac safety of trastuzumab combined in combination with pegylated liposomal doxorubicin and docetaxel in HER2-positive metastatic breast cancer: preliminary results of the eastern cooperative oncology group trial E3198. Proc. Am. Soc. Clin. Oncol (2003) 22:18 (Abstract 70).
   Google Scholar
• TRIGO J, CLIMENT MA, GIL M et al.: Cardiac safety and activity of a Phase I study of 3-weekly myocet in combination with weekly herceptin and paclitaxel in HERZ-positive (HERZ+) locally advanced or metastatic breast cancer (LA/MBC). Proc. Am. Soc. Clin. Oncol (2002) 21:61a (Abstract 242).
   Google Scholar
• QU G, PEREZ EA: Gemcitabine and targeted therapy in metastatic breast cancer. Semin. Oncol (2002) 29:44–52.
   PubMedGoogle Scholar
• BUNN PA, HELFRICH B, SORIANO AF et al.: Expression of HER2/neu in human lung cancer cell lines by immunohistochemistry and fluoresence in situ hybridization and its relationship with in vitro cytotoxicity by trastuzumab and chemotherapy agents. Clin. Cancer Res. (2003) 7:2239–3250.
   Google Scholar
• O'SHAUGHNESSY J: Gemcitabine and trastuzumab in metastatic breast cancer. Semin. Oncol (2003) 30:22–26.
   Google Scholar
• CHRISTODOULOU C, FOUNTZILAS G, RAZI E et al: Gemcitabine and trastuzumab combination as salvage treatment in patients with HERZ-positive metastatic breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:42 (Abstract 166).
   Google Scholar
• MILLER KD, SISK J, GIZE G et al: Phase II study of gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer; a Hosier Oncology Group Trial. Breast Cancer Res. Treat. (2002) 76:S113 (Abstract 437).
   Google Scholar
• HWANG JJ, MARSHALL JL: Capecitbine:fulfilling the promise of oral chemotherapy. Expert Opin. Pliarmacother. (2002) 3:733–743.
   PubMedGoogle Scholar
• BIGANZOLI L, MARTIN M, TWELVES C: Moving forward with capecitabine: a glimpse of the future. Oncologist (2002) 7:29–35.
   PubMed Web of Science ®Google Scholar
• BANGEMANN N, KHULE A, EBERT A et al.: Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC). Ann. Oncol (2000) 11:143 (Abstract 653P).
   Google Scholar
• HORTOBAGYI GN: Progress in systemic chemotherapy of primary breast cancer: an overview. Natl. Cancer Inst. Monogr. (2001):72–79.
   Google Scholar
• PICCART M: The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Res. Treat. (2003) 79\(Suppl. 1):525–534.
   Google Scholar
• KAUFMANN M, VON MINCKWITZ G, SMITH R et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. Clin. Oncol (2003) 21:2600–2608.
   Google Scholar
• KUERER HM, NEWMAN LA, SMITH TL et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol (1999) 17:460–469.
   PubMed Web of Science ®Google Scholar
• HURLEY J, DOLINY P, SILVA 0 et al: Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc. Am. Soc. Clin. Oncol (2002) 20:316 (Abstract 1871).
   Google Scholar
• BURSTEIN HJ, HARRIS LN, GELMAN R et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HERZ overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol (2003) 21:46–53.
   PubMed Web of Science ®Google Scholar
• •The first fully published paper studying the integration of trastuzumab in the neoadjuvant setting.
   Google Scholar
• HARRIS L, BURSTEIN HJ, GELMAN R et al.: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HERZ 3+/FISH+ Stage II/III breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:22 (Abstract 86).
   Google Scholar
• SCHIFFHAUER LM, GRIGGS JJ, AHRENDT GM et al.: Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:242 (Abstract 969).
   Google Scholar
• BINES J, MURAD A, LAGO S et al.: Multicenter brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:66 (Abstract 268).
   Google Scholar
• ALI S, COOMBES RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer (2002) 2:101–112.
   PubMed Web of Science ®Google Scholar
• WITTERS L, ENGLE L, LIPTON A: Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep. (2002) 9:1163–1166.
   PubMedGoogle Scholar
• LIPTON A, ALI SM, LEITZEL K et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol (2002) 20:1467–1472.
   PubMed Web of Science ®Google Scholar
• WITTON CJ, REEVES JR, GOING JJ et al.: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. Pathol (2003) 200:290–297.
   Google Scholar
• MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol (2003) 21:2787–2799.
   PubMed Web of Science ®Google Scholar
• MOULDER SL, ARTEAGA CL: A Phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin. Breast Cancer (2003) 4:142–145.
   PubMedGoogle Scholar
• HARRIS RE, ALSHAFIE GA, ABOU-ISSA H et al.: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. (2000) 60:2101–2103.
   PubMed Web of Science ®Google Scholar
• ALSHAFIE GA, ABOU-ISSA HM, SEIBERT K et al.: Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Reports (2000) 7:1377–1381.
   PubMed Web of Science ®Google Scholar
• DANG CT, DICKLER M, MOASSER M et al.: Celecoxib (C) and trastuzumab (Hercepting)(H) is feasible after H for HER-2/neu overexpressing (H2+) metastatic breast cancer (MBC) patients (pts). Proc. Am. Soc. Clin. Oncol (2002) 21:486. Abstract 2003.
   Google Scholar
• GIANNI L: The future of targeted therapy: combining novel agents. Oncology (Karge) (2003) 63\(Suppl. 1):57–46.
   Google Scholar
• BILOUS M, DOWSETT M, HANNA W et al.: Current perspectives on HERZ testing: a review of national testing guidelines. Mod. Patna (2003) 16:173–182.
   PubMed Web of Science ®Google Scholar
• ••This review provides useful informationconcerning the problem of optimal HER-2 testing.
   Google Scholar
• GELMON K, MACKEY J, VERMA S et al.: Efficacy and safety of herceptin in women with Her2-positive (HERZ+) metastatic breast cancer (MBC) who have progressed on a prior herceptin-containing regimen. Breast Cancer Res. Treat. (2002) 76:S113 (Abstract 440).
   Google Scholar
• MACKEY J, GELMON KA, VERMA S et al.: Continued use of Herceptin after disease progression in women with HERZ-positive (HERZ+) metastatic breast cancer (MBC): results from a retrospective analysis of 105 cases. Proc. Am. Soc. Chit. Oncol (2002) 21:52a (Abstract 207).
   Google Scholar
• FOUNTZILAS G, RAZIS E, TSAVDARIDIS D et al: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Chit. Breast Cancer (2003) 4:120–125.
   PubMedGoogle Scholar